Skip to main content

Table 3 Level of IgG antibodies in patients to different malaria antigens in relation to treatment outcome.

From: Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum

  Median level (25th and 75th percentiles)*  
Antigen TF, n = 53 ACPR, n = 47 P-value
GLURP-R0 0.0 (0.0–1.3) 8.4 (0.0–47.7) < 0.001
GLURP-R2 0.0 (0.0–5.0) 7.7 (0.0–49.8) < 0.001
AMA-1 24.3 (0.0–51.1) 24.5 (0.0–87.3) 0.25
CSP 5.8 (0.0–17.1) 10.2 (0.0–24.4) 0.42
CIDR1α 15.4 (3.3–61.7) 9.1 (0.0–30.2) 0.24
DBL2β 22.5 (6.9–45.6) 16.9 (3.4–58.3) 0.92
DBL4γ-DBL5δ 10.4 (1.6–38.6) 12.4 (3.0–44.0) 0.74
MSP-1 80.0 (6.7–144.4) 122.7 (29.3–162.0) 0.11
MSP-3 5.3 (1.1–12.6) 8.0 (2.5–18.9) 0.30
VSA1 15.5 (5.2–33.0) 19.8 (6.1–41.0) 0.58
VSA2 16.3 (4.1–30.9) 21.1 (7.6–38.7) 0.21
EBA-175 4.3 (0.0–14.1) 5.9 (0.0–21.0) 0.54
SCHIZONT 30.0 (12.9–51.0) 35.2 (11.1–80.2) 0.17
  1. TF: Parasitological or clinical treatment failure, ACPR: Adequate clinical and parasitological response. Patients receiving sulphadoxine-pyrimethamine (SP) or amodiaquine (AQ) are grouped together. *Median values of IgG level day 0 in arbitrary units (25th and 75th percentiles). P-values determined by Mann-Whitney rank-sum test. Similar tendencies were observed when restricting the analysis to those with a measurable antibody level only, and when analysing each drug arm separately. For definitions of antigens, see Figure 1 and in the method section.